Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models

María Rico; María Baglioni; Maryna Bondarenko; Nahuel Cesatti Laluce; Viviana Rozados; Nicolas André; Manon Carré; O. Graciela Scharovsky; Mauricio Menacho Márquez

doi:10.18632/oncotarget.13760

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models

María Rico, María Baglioni, Maryna Bondarenko, Nahuel Cesatti Laluce, Viviana Rozados, Nicolas André, Manon Carré, O. Graciela Scharovsky and Mauricio Menacho Márquez _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:2874-2889. https://doi.org/10.18632/oncotarget.13760

Metrics: PDF 3103 views | HTML 5238 views | ?

Abstract

María Rico1,2,*, María Baglioni1,*, Maryna Bondarenko3, Nahuel Cesatti Laluce1, Viviana Rozados1, Nicolas André3,4,5, Manon Carré3, O. Graciela Scharovsky1,2,5, Mauricio Menacho Márquez1,2

1Instituto de Genética Experimental, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Argentina

2El Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina

3Aix-Marseille Université, Inserm UMR_S 911, Centre de Recherche en Oncologie biologique et Oncopharmacologie, Faculté de Pharmacie, Marseille, France

4Service d'Hématologie and Oncologie Pédiatrique, AP-HM, Marseille, France

5Metronomics Global Health Initiative, Marseille, France

*These authors contributed equally and are co-first authors

Correspondence to:

Mauricio Menacho Márquez, email: [email protected]

Keywords: breast cancer, metronomics, drug repositioning, metformin, propranolol

Received: July 22, 2016 Accepted: November 22, 2016 Published: December 01, 2016

ABSTRACT

Discovery of new drugs for cancer treatment is an expensive and time-consuming process and the percentage of drugs reaching the clinic remains quite low.

Drug repositioning refers to the identification and development of new uses for existing drugs and represents an alternative drug development strategy.

In this work, we evaluated the antitumor effect of metronomic treatment with a combination of two repositioned drugs, metformin and propranolol, in triple negative breast cancer models.

By in vitro studies with five different breast cancer derived cells, we observed that combined treatment decreased proliferation (P < 0.001), mitochondrial activity (P < 0.001), migration (P < 0.001) and invasion (P < 0.001). In vivo studies in immunocompetent mice confirmed the potential of this combination in reducing tumor growth (P < 0.001) and preventing metastasis (P < 0.05).

Taken together our results suggest that metformin plus propranolol combined treatment might be beneficial for triple negative breast cancer control, with no symptoms of toxicity.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13760

Publication Alerts

Post-Publication Promotion

Research Papers:

Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models

Abstract